Effectiveness of Coronavirus Disease 2019 (COVID-19) mRNA Vaccines Against Infection During an Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Beta (B.1.351) Variant in a Skilled Nursing Facility: Virginia, March-April 2021

Clin Infect Dis. 2022 Oct 3;75(Suppl 2):S155-S158. doi: 10.1093/cid/ciac526.

Abstract

In April 2021, we assessed mRNA vaccine effectiveness (VE) in the context of a COVID-19 outbreak in a skilled nursing facility. Among 28 cases, genomic sequencing was performed on 4 specimens on 4 different patients, and all were classified by sequence analysis as the Beta (B.1.351) variant. Adjusted VE among residents was 65% (95% confidence interval: 25-84%). These findings underscore the importance of vaccination for prevention of COVID-19 in skilled nursing facilities.

Keywords: SARS-CoV-2; skilled nursing facility; vaccine effectiveness.

MeSH terms

  • COVID-19 Vaccines
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Disease Outbreaks / prevention & control
  • Humans
  • RNA, Messenger
  • SARS-CoV-2* / genetics
  • Vaccines, Synthetic
  • Virginia
  • mRNA Vaccines

Substances

  • COVID-19 Vaccines
  • RNA, Messenger
  • Vaccines, Synthetic
  • mRNA Vaccines

Supplementary concepts

  • SARS-CoV-2 variants